Driscoll Rimma, Executive Vice President at an undisclosed firm, has executed 34 trades across two companies—Zoetis (ZTS) and DexCom (DXCM)—since early 2024, with a clear net selling bias. According to SEC Form 4 filings, Rimma’s total buy activity amounts to $79,990.82, while sales total $111,892.49, reflecting a $31,901.67 net outflow. The majority of transactions involve Zoetis, with notable sales including a $33,741.72 disposition on February 10, 2024, followed by smaller sales of $11,340.38 and $9,811.34 in early February 2026. More recently, on February 19, 2026, Rimma sold $22,783.12 worth of ZTS shares. Purchases have been sporadic and comparatively modest, with the largest being a $7,000 acquisition in October 2025 and a $6,000 buy in January 2026.
The trading pattern shows a shift toward divestment, particularly in early 2026, with multiple sales and no recent buys. While some transactions—such as those coded "M" (merger or acquisition-related) or "A" (award or grant)—carry no reported value, the monetized sales underscore a consistent reduction in exposure to Zoetis. The only activity involving DexCom (DXCM) was a valueless award transaction in May 2025, suggesting minimal engagement with that holding. Rimma’s trades, concentrated in Zoetis, reveal a gradual unwinding of positions over the past two years, with no new purchases to offset the disposals. The absence of recent buying activity further reinforces this trend.
AI-assisted summary